Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C23H28O9 |
Molar mass | 448.468 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Sergliflozin etabonate ( INN/ USAN, [1] [2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.[ citation needed]
Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. [3] [4]
Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.